【摘要】：目的:比較T-VD方案(硼替佐米+地塞米松+沙利度胺)與T-VAD方案(長春新堿+阿霉素+地塞米松+沙利度胺)治療多發(fā)性骨髓瘤(multiple myeloma,MM)的臨床效果。方法:選取2010年4月至2012年4月本院收治的30例行T-VD方案化療的MM患者(T-VD組)和30例行T-VAD方案化療的MM患者(對照組)作為研究對象,對比2組患者化療效果及遠(yuǎn)期生存情況。結(jié)果:T-VD組CR率和ORR明顯高于T-VAD組(P0.05);T-VD組非輕鏈型與輕鏈型患者ORR均明顯高于T-VAD組(P0.05);T-VD組非輕鏈型與輕鏈型患者ORR對比,差異無統(tǒng)計(jì)學(xué)意義(P0.05);T-VAD組非輕鏈型與輕鏈型患者ORR對比,差異無統(tǒng)計(jì)學(xué)意義(P0.05);T-VD組Ⅰ-Ⅱ期患者ORR與T-VAD組Ⅰ-Ⅱ期患者對比無顯著差異(P0.05);T-VD組Ⅲ期患者ORR明顯高于T-VAD組Ⅲ期患者(P0.05);T-VD組Ⅰ-Ⅱ期患者ORR與Ⅲ期患者對比,差異無統(tǒng)計(jì)學(xué)意義(P0.05);T-VAD組Ⅰ-Ⅱ期患者ORR明顯高于Ⅲ期患者(P0.05);T-VD組患者化療后血清M蛋白、骨髓瘤細(xì)胞、β2-MG水平均明顯低于T-VAD組(P0.05);T-VD組患者的感染和周圍神經(jīng)病變發(fā)生率及無進(jìn)展生存時(shí)間均明顯高于對照組(P0.05)。結(jié)論:T-VD方案治療MM患者的效果優(yōu)于T-VAD方案,且其效果不受分型與分期影響,但會加重部分毒副作用,臨床需謹(jǐn)慎選擇。
[Abstract]:Objective: to compare the clinical effects of T-VD regimen (bortezomil dexamethasone thalidomide) and T-VAD regimen (vincristine adriamycin dexamethasone thalidomide) in the treatment of multiple myeloma (multiple myeloma,MM). Methods: from April 2010 to April 2012, 30 MM patients treated with T-VD regimen chemotherapy (T-VD group) and 30 MM patients with T-VAD regimen chemotherapy (control group) were selected as the study subjects. The effect of chemotherapy and long-term survival were compared between the two groups. Results: the rate of CR and ORR in T-VD group was significantly higher than that in T-VAD group (P0.05), ORR in T-VD group was significantly higher than that in T-VAD group (P0.05). There was no significant difference in ORR between non-light chain type and light chain type in T-VD group (P0.05), and there was no significant difference in ORR between non-light chain type and light chain type in T-VAD group (P0.05). There was no significant difference between ORR and T-VAD in stage 鈪，

本文編號：2344742